Stocks
AnaptysBio Financial Statements (ANAB) |
||||||||||
| AnaptysBiosmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 02.03.2020 | 25.02.2021 | 07.03.2022 | 01.03.2023 | 11.03.2024 | 11.03.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 8.00 | 75.0 | 63.2 | 10.3 | 17.2 | 17.2 | |||
| Operating Income, bln rub | -107.4 | -23.9 | -56.8 | -115.2 | -164.4 | -164.4 | ||||
| EBITDA, bln rub | ? | -96.4 | -19.4 | -56.3 | -107.6 | -135.8 | -143.8 | |||
| Net profit, bln rub | ? | -97.3 | -19.9 | -57.2 | -128.7 | -163.6 | -167.8 | |||
| OCF, bln rub | ? | -69.5 | -14.2 | -45.9 | -73.6 | -120.8 | -120.8 | |||
| CAPEX, bln rub | ? | 0.805 | 0.569 | 1.37 | 0.358 | 0.807 | 0.807 | |||
| FCF, bln rub | ? | -70.3 | -14.7 | -47.3 | -74.0 | -121.6 | -121.6 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 115.4 | 98.9 | 120.0 | 125.4 | 174.2 | 174.2 | ||||
| Cost of production, bln rub | 99.3 | 80.0 | 98.5 | 2.34 | 2.38 | 2.38 | ||||
| R&D, bln rub | 99.3 | 80.0 | 98.5 | 88.8 | 132.3 | 132.3 | ||||
| Interest expenses, bln rub | 1.04 | 0.000 | 1.45 | 21.1 | 18.1 | 18.1 | ||||
| Assets, bln rub | 435.2 | 416.6 | 643.1 | 610.4 | 452.4 | 452.4 | ||||
| Net Assets, bln rub | ? | 405.0 | 396.7 | 356.4 | 262.1 | 88.1 | 88.1 | |||
| Debt, bln rub | 2.25 | 0.342 | 21.0 | 19.5 | 17.8 | 17.8 | ||||
| Cash, bln rub | 374.2 | 393.7 | 548.1 | 441.2 | 390.9 | 390.9 | ||||
| Net debt, bln rub | -372.0 | -393.3 | -527.1 | -421.8 | -373.1 | -373.1 | ||||
| Ordinary share price, rub | 16.3 | 21.5 | 34.8 | 31.0 | 21.4 | 16.2 | ||||
| Number of ordinary shares, mln | 27.1 | 27.3 | 27.4 | 28.2 | 26.9 | 26.6 | ||||
| Market cap, bln rub | 440 | 587 | 953 | 873 | 577 | 430 | ||||
| EV, bln rub | ? | 68 | 194 | 426 | 451 | 204 | 57 | |||
| Book value, bln rub | 405 | 397 | 356 | 262 | 88 | 88 | ||||
| EPS, rub | ? | -3.60 | -0.73 | -2.08 | -4.57 | -6.08 | -6.31 | |||
| FCF/share, rub | -2.60 | -0.54 | -1.72 | -2.63 | -4.52 | -4.57 | ||||
| BV/share, rub | 15.0 | 14.5 | 13.0 | 9.31 | 3.27 | 3.31 | ||||
| EBITDA margin, % | ? | -1 206% | -25.8% | -89.2% | -1 046% | -791.7% | -837.9% | |||
| Net margin, % | ? | -1 217% | -26.6% | -90.5% | -1 251% | -953.7% | -978.1% | |||
| FCF yield, % | ? | -16.0% | -2.51% | -4.96% | -8.47% | -21.1% | -28.3% | |||
| ROE, % | ? | -24.0% | -5.02% | -16.0% | -49.1% | -185.7% | -190.5% | |||
| ROA, % | ? | -22.4% | -4.78% | -8.89% | -21.1% | -36.2% | -37.1% | |||
| P/E | ? | -4.52 | -29.5 | -16.7 | -6.78 | -3.52 | -2.56 | |||
| P/FCF | -6.25 | -39.9 | -20.2 | -11.8 | -4.74 | -3.54 | ||||
| P/S | ? | 55.0 | 7.83 | 15.1 | 84.8 | 33.6 | 25.1 | |||
| P/BV | ? | 1.09 | 1.48 | 2.67 | 3.33 | 6.55 | 4.88 | |||
| EV/EBITDA | ? | -0.70 | -10.00 | -7.56 | -4.19 | -1.50 | -0.40 | |||
| Debt/EBITDA | 3.86 | 20.3 | 9.36 | 3.92 | 2.75 | 2.60 | ||||
| R&D/CAPEX, % | 12 340% | 14 064% | 7 211% | 24 804% | 16 392% | 16 392% | ||||
| CAPEX/Revenue, % | 10.1% | 0.76% | 2.16% | 3.48% | 4.70% | 4.70% | ||||
| AnaptysBio shareholders | ||||||||||
